Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Market for Drugs for Hyperlipidemia to Exceed ¥400 Bil. in 2013: Fuji-Keizai Data Book
May 4, 2009
- NEDO to Start Large-Scale Clinical Trial on AD
May 4, 2009
- Shionogi to Develop In-house Products by Sugar Chain Analysis, Molecular Imaging
May 4, 2009
- Large-Scale Trial on Risk of Bone Fractures due to TZD Underway in Europe
May 4, 2009
- Gov't to Earmark ¥79.0 Bil. to Promote Development of Unapproved Drugs
May 4, 2009
- Kyowa Kirin Aiming at Becoming Global Specialty Pharma
May 4, 2009
- R&D NEWS IN BRIEF
May 4, 2009
- Shionogi Expands Support Systems for Female MRs
May 4, 2009
- Pharmacists Should Be Encouraged to Dispense More Generics
May 4, 2009
- GSK to Lead Respiratory Drug Market with Adoair
May 4, 2009
- JSHP to More Actively Cooperate with the Use of More Generics
May 4, 2009
- Toyota Tsusho to Represent ChemRoutes in Japan
May 4, 2009
- Patient Education Important to Promote Use of Generics
May 4, 2009
- BUSINESS NEWS IN BRIEF
May 4, 2009
- SSP Aims at ¥2 Bil. with Switch OTC Version of Diclofenac
May 4, 2009
- PhRMA to Support NHI Price Maintenance System: Mr Sekiguchi
May 4, 2009
- Magnesium Oxide Should Remain Class 3 OTC Drug: Society
May 4, 2009
- Korosho to Speed Up Development of Anticancer, Pediatric Drugs Using Supplementary Budget
May 4, 2009
- Focusing on the Task at Hand
May 4, 2009
- More Companies Show Interest in Collaborative Multinational Trials: Mr Nakagaki
May 4, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…